Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19

Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19

The SARS-CoV-2 virus emerged in December 2019 in Wuhan, China and then spread rapidly all over the world. Scientists are intensifying their research efforts in order to find antivirals specific to the virus and vaccines to treat or prevent COVID-19. Now, for a medicative cure for COVID-19, several d...

Полное описание

Библиографические подробности
Главный автор:	Amrit Krishna Mitra
Формат:	Статья
Язык:	English
Опубликовано:	AIMS Press 2020-12-01
Серии:	AIMS Molecular Science
Предметы:	covid-19 sars-cov-2 chloroquine hydroxychloroquine lopinavir ritonavir remdesivir favipiravir vitamin c convalescent plasma
Online-ссылка:	http://www.aimspress.com/article/10.3934/molsci.2020012?viewType=HTML

Схожие документы

Review of Clinical Trials in COVID-19: Trying to Solve the Clinicians’ Conundrum
по: Amita Athavale, и др.
Опубликовано: (2020-07-01)

COVID-19: An Update about the Discovery Clinical Trial
по: Jean Jacques Vanden Eynde
Опубликовано: (2020-05-01)

Therapeutic Strategies in the Management of COVID-19
по: Rajashri R. Naik, и др.
Опубликовано: (2021-02-01)

A narrative review of antiviral drugs used for COVID-19 pharmacotherapy
по: Subodh Kumar, и др.
Опубликовано: (2021-01-01)

COVID-19: A Brief Overview of the Discovery Clinical Trial
по: Jean Jacques Vanden Eynde
Опубликовано: (2020-04-01)

A Comparative Study of Approved Drugs for SARS-CoV-2 by Molecular Docking
по: Achal Mishra, и др.
Опубликовано: (2021-06-01)

COVID-19 possible medical treatments
по: Marzieh Mohammadi, и др.
Опубликовано: (2021-01-01)

Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)
по: Abhi Bhadra, и др.
Опубликовано: (2020-05-01)

Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
по: Shahamah Jomah, и др.
Опубликовано: (2020-09-01)

Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis
по: Sultan Ayoub Meo, и др.
Опубликовано: (2020-10-01)

Comparison of effectiveness of various treatment strategies in COVID-19 patients: A Systematic Review
по: Muhammad Shehryar Hussain, и др.
Опубликовано: (2020-08-01)

Pharmacological management of COVID-19
по: Veena Raghunathan, и др.
Опубликовано: (2020-01-01)

An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
по: A. S. Kolbin
Опубликовано: (2020-05-01)

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
по: B. K. Romanov
Опубликовано: (2020-09-01)

Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
по: Xinni Xu, и др.
Опубликовано: (2020-05-01)

The Rationale for Potential Pharmacotherapy of COVID-19
по: Maha Saber-Ayad, и др.
Опубликовано: (2020-05-01)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
по: Qomara WF, и др.
Опубликовано: (2021-11-01)

Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities
по: Milo Gatti, и др.
Опубликовано: (2021-02-01)

Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study
по: David Grimaldi, и др.
Опубликовано: (2020-10-01)

COVID-19 treatment in children: A systematic review and meta-analysis
по: Prateek Kumar Panda, и др.
Опубликовано: (2021-01-01)

Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
по: Alina Kröker, и др.
Опубликовано: (2021-11-01)

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations
по: Stanković Biljana, и др.
Опубликовано: (2020-01-01)

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
по: Hayato Koba, и др.
Опубликовано: (2020-12-01)

Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
по: Abubakar AR, и др.
Опубликовано: (2020-12-01)

Clinical evaluation of selected Pharmacological Treatments used for Coronavirus (COVID-19) pandemic
по: hasan mohammed altemimy
Опубликовано: (2020-06-01)

Efficacy of lopinavir/ritonavir plus interferon beta compared to hydroxychloroquine in the treatment of COVID-19: A retrospective observational study
по: Motahareh Amirizadeh, и др.
Опубликовано: (2023-01-01)

High Prevalence of Potential Drug-Drug Interactions Among Patients Treated with Off-label Therapies for COVID-19
по: Allan Ramos-Esquivel, и др.
Опубликовано: (2022-06-01)

Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents
по: Shagun B Shah, и др.
Опубликовано: (2021-01-01)

Progress in the Research and Development of Anti-COVID-19 Drugs
по: Lianzhou Huang, и др.
Опубликовано: (2020-07-01)

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial
по: A. Abayomi, и др.
Опубликовано: (2021-12-01)

Measuring the energy for the molecular graphs of antiviral agents: Hydroxychloroquine, Chloroquine and Remdesivir
по: Muhammad Haroon Aftab, и др.
Опубликовано: (2024-01-01)

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
по: Mehdi Hassaniazad, и др.
Опубликовано: (2020-10-01)

Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as MPro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
по: Woon Yi Law, и др.
Опубликовано: (2020-11-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
по: Ayşe BATIREL, и др.
Опубликовано: (2021-12-01)

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
по: Min Joo Choi, и др.
Опубликовано: (2021-01-01)

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
по: Justin T. Denholm, и др.
Опубликовано: (2020-07-01)

Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations
по: Paolo Gaibani, и др.
Опубликовано: (2021-03-01)

Cardiotoxic Drugs Used in the Treatment of COVID-19
по: A. S. Zmitrukevich, и др.
Опубликовано: (2024-01-01)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
по: Nils von Hentig, и др.
Опубликовано: (2021-05-01)

Scoping insight on antiviral drugs against COVID-19
по: Ahmed S. Ali, и др.
Опубликовано: (2021-10-01)